NASDAQ:SEPN Septerna Q3 2026 Earnings Date & Estimates $36.44 +0.02 (+0.06%) As of 01:45 PM Eastern This is a fair market value price provided by Massive. Learn more. Septerna is estimated to report Q3 2026 earnings on Monday, November 9, 2026. The conference call is scheduled for November 10, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 9, 2026Conference Call DateNovember 10, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Septerna in Q3 2026Septerna is expected to post earnings of -$0.4150 per share on revenue of $20.78 million. In the same quarter a year earlier Septerna reported -$0.09 per share on revenue of $21.50 million. Septerna last reported on August 10, 2026, posting -$0.29 per share and beating the -$0.4260 consensus estimate. Septerna has beaten the consensus EPS estimate in 3 of its last 7 quarters.Consensus EstimatesConsensus EPS-$0.4150Expected Revenue$20.78 millionPrior-Year EPS-$0.09Prior-Year Revenue$21.50 millionExpected Revenue Growth-3.3%Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.29 (Beat by +$0.1360)Last Quarter Revenue$26.75 millionEPS Beat Rate3 of last 7 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Septerna Q3 2026 Earnings FAQ When does Septerna report Q3 2026 earnings? Septerna (NASDAQ:SEPN) is estimated to report Q3 2026 earnings on Monday, November 9, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Septerna's Q3 2026 earnings call? Septerna's Q3 2026 earnings conference call is scheduled for Tuesday, November 10, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Septerna? Analysts expect Septerna to post earnings of -$0.4150 per share for Q3 2026. How much revenue is Septerna expected to report? The consensus revenue estimate for Septerna is $20.78 million for Q3 2026. Septerna Earnings HeadlinesSepterna, Inc. (NASDAQ:SEPN) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesOctober 11 at 6:29 AM | americanbankingnews.comSepterna (SEPN) Heads To Healthcare Conferences, Is The Valuation Already Too Rich?September 15, 2026 | finance.yahoo.comElon says the ‘S’ wordElon Musk and Sam Altman have sued each other and feuded for years. Yet within days of one another, both men described the same moment in strikingly similar terms: a technological tipping point they call the Singularity. James Altucher says the idea once belonged to science fiction. Now he connects it to a move Musk could make as soon as October 21, and lays out what both men see coming in a short presentation.October 14 at 1:00 AM | Paradigm Press (Ad)Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)September 10, 2026 | globenewswire.comSepterna to Participate in Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comSepterna names Rajiv Patni as CMOAugust 25, 2026 | msn.comSee More Septerna Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Septerna? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Septerna and other key companies, straight to your email. Email Address About SepternaSepterna (NASDAQ:SEPN) is a clinical-stage biopharmaceutical company focused on discovering and developing oral medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in numerous biological processes and are established targets for therapies across a range of diseases. The company uses its proprietary Native Complex Platform to study GPCRs in their native state and identify small-molecule medicines for targets that have historically been difficult to address. Septerna’s investigational pipeline includes oral GPCR modulators, including SEP-786, an oral parathyroid hormone 1 receptor agonist being developed for the potential treatment of hypoparathyroidism. Septerna was founded by scientists with expertise in GPCR biology and drug discovery and is headquartered in San Diego, California. The company has no marketed products and is advancing its candidates through clinical development and research activities intended to support treatments for patients in the United States and other global markets. Patrick Horn, Ph.D., serves as the company’s president and chief executive officer.View Septerna ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenPBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough Road Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
